Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Junta de Andalucia | OTHER_GOV |
| Statistical analysis: SEPLIN Soluciones EstadÃsticas | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of this intervention study is to evaluate the efficacy of Lactobacillus fermentum CECT5716 to reduce the presence in the milk of genera Staphylococcus and Streptococcus as risk factors for mastitis in women with breast pain
Type of study Nutritional intervention study, multicenter, randomized, blinded, parallel group included 25 women per group
Statistical calculation of sample size. The calculation of sample size was calculated by the company SEPLIN Solutions Statistics. The primary endpoint was the bacterial count of in milk. The sample size obtained to observe a difference of 1 log10, with a power of 0.80 and a significance level of 0.05 was 20 volunteers per group.
Randomization Randomization was performed using a list of random numbers generated by computer. Subjects will be randomized in a strictly sequential.
If a subject is removed from the test, the number that was assigned randomization not be reused again.
Overall design and outline of the study At visit 1 we require the informed consent of the patient. It will take the milk sample, we will review the implementation of the inclusion and exclusion criteria. Be randomized and explain the treatment guidelines to be followed, the data to be collected and medical appointments that must go (2 and 3 weeks). It will complete the pain assessment questionnaire (MQP) and nutrition survey.
On visits 2, 3 and 4 corresponding to 1, 2 and 3 weeks of intervention will collect milk sample pain assessment survey and nutrition survey.
Milk samples (5 mL) were collected aseptically in sterile tubes to be frozen immediately until analysis to be carried out within seven days.
Intervention duration The intervention will last three weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| fermentum 3x | Experimental | Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day |
|
| fermentum 6x | Experimental | Lactobacillus fermentum CECT5716 at 6x10e9cfu/day |
|
| fermentum 9x | Experimental | Lactobacillus fermentum CECT5716 at 9x10e9cfu/day |
|
| maltodextrin | Placebo Comparator | maltodextrin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lactobacillus fermentum CECT5716 | Dietary Supplement |
| ||
| Placebo Comparator: maltodextrin |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline Staphylococcus count at 3 weeks | Counts of Staphylococcus in breast milk | 0, 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline Streptococcus counts at 3 weeks | Streptococcus counts in breast milk | 0, 3 weeks |
| Change from Breast pain score at 3 weeks | evaluation of breast pain |
Not provided
Inclusion Criteria:
· breast-feeding women
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Dr. Miguel A DÃaz López, Doctor | Gynecology Service of Virgen de las Nieves Hospital, Granada (Spain) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Virgen de las Nieves | Granada | Granada | 18012 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32987448 | Derived | Crepinsek MA, Taylor EA, Michener K, Stewart F. Interventions for preventing mastitis after childbirth. Cochrane Database Syst Rev. 2020 Sep 29;9(9):CD007239. doi: 10.1002/14651858.CD007239.pub4. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D059373 | Mastodynia |
| D008413 | Mastitis |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
Placebo |
|
| 0, 3 weeks |
| D011644 | Puerperal Disorders |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |